DE60140270D1 - Lactamverbindungen und deren medizinische verwendung - Google Patents

Lactamverbindungen und deren medizinische verwendung

Info

Publication number
DE60140270D1
DE60140270D1 DE60140270T DE60140270T DE60140270D1 DE 60140270 D1 DE60140270 D1 DE 60140270D1 DE 60140270 T DE60140270 T DE 60140270T DE 60140270 T DE60140270 T DE 60140270T DE 60140270 D1 DE60140270 D1 DE 60140270D1
Authority
DE
Germany
Prior art keywords
diabetic
medical use
lactam compounds
agent
adiposis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140270T
Other languages
German (de)
English (en)
Inventor
Y Iino
T Ikenoue
N Kondo
H Matsueda
T Hatanaka
R Hirama
Y Masuzawa
F Ohta
A Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE60140270D1 publication Critical patent/DE60140270D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
DE60140270T 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung Expired - Lifetime DE60140270D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
DE60140270D1 true DE60140270D1 (de) 2009-12-03

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140270T Expired - Lifetime DE60140270D1 (de) 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung

Country Status (26)

Country Link
US (3) US7153850B2 (cg-RX-API-DMAC7.html)
EP (1) EP1346993B1 (cg-RX-API-DMAC7.html)
JP (2) JP3826400B2 (cg-RX-API-DMAC7.html)
KR (1) KR100826818B1 (cg-RX-API-DMAC7.html)
CN (2) CN1269818C (cg-RX-API-DMAC7.html)
AT (1) ATE446297T1 (cg-RX-API-DMAC7.html)
AU (3) AU1850202A (cg-RX-API-DMAC7.html)
BG (1) BG107857A (cg-RX-API-DMAC7.html)
BR (1) BR0115852A (cg-RX-API-DMAC7.html)
CA (1) CA2430124C (cg-RX-API-DMAC7.html)
CZ (1) CZ20031520A3 (cg-RX-API-DMAC7.html)
DE (1) DE60140270D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331299T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0400806A3 (cg-RX-API-DMAC7.html)
IL (1) IL156158A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004876A (cg-RX-API-DMAC7.html)
NO (1) NO325401B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ526164A (cg-RX-API-DMAC7.html)
PL (1) PL362835A1 (cg-RX-API-DMAC7.html)
RU (1) RU2287530C2 (cg-RX-API-DMAC7.html)
SK (1) SK6582003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI241302B (cg-RX-API-DMAC7.html)
UA (1) UA76969C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002044180A1 (cg-RX-API-DMAC7.html)
YU (1) YU42603A (cg-RX-API-DMAC7.html)
ZA (1) ZA200304100B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
WO2005042536A1 (ja) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
CA2553329A1 (en) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. New fused polycyclic compounds
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
JP5056412B2 (ja) 2005-04-28 2012-10-24 味の素株式会社 新規ラクタム化合物
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
EP3238723B1 (en) * 2014-12-22 2020-02-05 EA Pharma Co., Ltd. Drug for treating disorders of corneal epithelium
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
TWI820289B (zh) * 2019-01-23 2023-11-01 醣解生醫股份有限公司 β-內醯胺類化合物或其鹽於長效預防或治療葡萄糖代謝失調之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
ES2229523T3 (es) 1997-07-30 2005-04-16 Wyeth Agonistas triciclicos de la vasopresina.
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Also Published As

Publication number Publication date
HUP0400806A2 (hu) 2004-07-28
NO325401B1 (no) 2008-04-21
CA2430124C (en) 2011-01-11
PL362835A1 (en) 2004-11-02
ATE446297T1 (de) 2009-11-15
SK6582003A3 (en) 2003-09-11
CZ20031520A3 (cs) 2003-10-15
US7326701B2 (en) 2008-02-05
IL156158A0 (en) 2003-12-23
AU2002218502B2 (en) 2006-09-21
US7153850B2 (en) 2006-12-26
JPWO2002044180A1 (ja) 2004-04-02
CN1911915A (zh) 2007-02-14
US20040048847A1 (en) 2004-03-11
YU42603A (sh) 2006-03-03
KR100826818B1 (ko) 2008-05-02
NO20032439L (no) 2003-07-18
AU2006241377A1 (en) 2006-12-14
UA76969C2 (en) 2006-10-16
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
AU1850202A (en) 2002-06-11
US20080096862A1 (en) 2008-04-24
CA2430124A1 (en) 2002-06-06
JP4505753B2 (ja) 2010-07-21
WO2002044180A1 (en) 2002-06-06
MXPA03004876A (es) 2004-01-27
BG107857A (bg) 2004-06-30
EP1346993A4 (en) 2005-12-21
CN100577651C (zh) 2010-01-06
EP1346993B1 (en) 2009-10-21
HUP0400806A3 (en) 2007-11-28
ZA200304100B (en) 2004-08-22
KR20030051893A (ko) 2003-06-25
ES2331299T3 (es) 2009-12-29
CN1487940A (zh) 2004-04-07
NZ526164A (en) 2004-09-24
CN1269818C (zh) 2006-08-16
JP3826400B2 (ja) 2006-09-27
US20060189597A1 (en) 2006-08-24
TWI241302B (en) 2005-10-11
RU2287530C2 (ru) 2006-11-20
EP1346993A1 (en) 2003-09-24
BR0115852A (pt) 2003-12-23
JP2006213732A (ja) 2006-08-17
AU2006241377B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
ATE446297T1 (de) Lactamverbindungen und deren medizinische verwendung
NL300985I2 (en) mogamulizumab
DE60022226D1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
ATE412387T1 (de) Medizinische vorrichtungen
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DE69821633D1 (de) Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält
AU2001276689A1 (en) Novel remedies for cancer
ATE438626T1 (de) 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
BR0014775B1 (pt) misturas antimicrobianas de 1,3-bis (hidroximetil) -5,5-dimetilidantoina e 1,2-benzisotiazolin-3-ona.
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
DE59910758D1 (de) Transdermales pflaster, enthaltend mindestens einen die blutfettwerte beeinflussenden wirkstoff
WO2001039723A3 (en) Triazospiro compounds having nociceptin receptor affinity
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
NO985571L (no) Legemiddel for autoimmunsykdommer
ATE456651T1 (de) Metalloprotease mit aggrecanase-aktivität
TW200509980A (en) Parasiticidal composition
ATE454151T1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
DE60008607D1 (de) Fungizide Mischung
DE69012742D1 (de) Azolderivate und fungizide Medikamente, diese als wirkende Komponente enthaltend.
ATE285236T1 (de) Antivirale zusammensetzungen enthaltend yohimbin als therapeutischen wirkstoff
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition